Edition:
India

Teva Pharmaceutical Industries Ltd (TEVA.N)

TEVA.N on New York Stock Exchange

33.23USD
20 Jan 2017
Change (% chg)

$-0.24 (-0.72%)
Prev Close
$33.47
Open
$33.40
Day's High
$33.56
Day's Low
$33.17
Volume
1,876,627
Avg. Vol
1,886,671
52-wk High
$64.31
52-wk Low
$33.17

TEVA.N

Chart for TEVA.N

About

Teva Pharmaceutical Industries Limited is a global pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. It has a global portfolio of approximately 1,000... (more)

Overall

Beta: 0.59
Market Cap(Mil.): $34,211.34
Shares Outstanding(Mil.): 1,014.36
Dividend: 0.34
Yield (%): 4.09

Financials

  TEVA.N Industry Sector
P/E (TTM): 19.19 29.51 30.38
EPS (TTM): 1.73 -- --
ROI: 3.34 15.44 14.86
ROE: 5.87 16.62 16.28

BRIEF-Teva receives FDA approval for VANTRELATM ER

* Teva receives FDA approval for VANTRELATM ER (hydrocodone bitartrate) extended-release tablets formulated with proprietary abuse deterrence technology Source text for Eikon: Further company coverage:

18 Jan 2017

Eli Lilly defeats Teva appeal over Alimta cancer drug

A U.S. appeals court on Thursday said Eli Lilly and Co may block Teva Pharmaceutical Industries Ltd from selling a generic equivalent of its top-selling lung cancer drug Alimta, in a closely-watched patent case.

12 Jan 2017

Teva loses appeal against Eli Lilly in Alimta patent case

Jan 12 A U.S. appeals court on Thursday ruled in favor of Eli Lilly & Co in a closely-watched patent case, saying a lower court judge correctly found Teva Pharmaceutical Industries Ltd and other companies liable for inducing the infringement of Lilly's lung cancer drug Alimta.

12 Jan 2017

BRIEF-U.S. appeals court rejects Teva appeal in Lilly patent case over Alimta

Jan 12 U.S. Appeals Court rules for Eli Lilly and against Teva Pharmaceutical in Alimta patent case -- court ruling

12 Jan 2017

BRIEF-Teva Pharmaceutical Industries sees 2017 non-GAAP EPS $4.90 - $5.30

* Sees 2017 non-GAAP net revenue $23.8 billion - $24.5 billion

06 Jan 2017

UPDATE 2-Teva's 2017 revenue, profit forecasts miss as launch delays weigh

* Sees mid-to-single digit pct price erosion in U.S. generics

06 Jan 2017

CORRECTED-UPDATE 1-Teva forecasts 2017 revenue, profit below estimates

Jan 6 Teva Pharmaceutical Industries Ltd , the world's biggest generic drug maker, forecast 2017 revenue and profit missing analysts' estimates.

06 Jan 2017

CORRECTED-Teva forecasts 2017 revenue, profit below estimates

Jan 6 Teva Pharmaceutical Industries Ltd , the world's biggest generic drug maker, forecast 2017 revenue and profit below analysts' estimates.

06 Jan 2017

BRIEF-Teva projects more than $750 mln in sales in U.S. product launches in 2017

* Teva CEO: we continue to see challenges as a company and as an industry and we expect some of these challenges to continue in 2017: conf call

06 Jan 2017

BRIEF-Teva expects to see mid single-digit price erosion in U.S.

* Teva Exec: we expect to see mid single-digit price erosion to continue in our base business in the United States: conf call

06 Jan 2017

Competitors

  Price Chg
Novartis AG (NOVN.S) CHF70.90 -0.20
Biogen Inc (BIIB.OQ) $280.66 +0.31

Earnings vs. Estimates